Immunic – Consensus Indicates Potential 241.9% Upside

Broker Ratings

Immunic found using ticker (IMUX) have now 6 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 72 and 45 with a mean TP of 60.83. With the stocks previous close at 17.79 this is indicating there is a potential upside of 241.9%. There is a 50 day moving average of 17.32 and the 200 moving average now moves to 17.65. The company has a market capitalisation of $406m. Find out more information at:

Immunic, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn’s disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic is headquartered in New York, New York.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index